A - 130 Effectiveness of Beta-Amyloid Immunotherapy and Monoclonal Antibodies in Patients with Early Onset Alzheimer’s between the Ages of 45–60 Years

Abstract Objective This comprehensive systematic review examines various therapeutic approaches for Alzheimer’s Disease (ad), with a specific emphasis on immunotherapy targeting beta-amyloid and tau pathology. Data Selection Data were sourced from peer-reviewed journals, databases (e.g., PubMed, PsychInfo, Scielo, Google Scholar), and relevant conference proceedings from inception to present. Search terms included variations of “Alzheimer’s disease,” “clinical trials,” “monoclonal antibodies,” “beta amyloid,” “immunotherapy”. Selection criteria emphasized relevance to ad therapy, randomized controlled trials, and clinical outcomes. A total of 24 studies from 2013 to 2023 were reviewed, meeting robust study design, sample size, and therapeutic relevance were chosen. Data extraction followed standardized guidelines for abstracting key information, including study design, participant characteristics, interventions, and outcome measures. Data Synthesis The review synthesized recent studies on Alzheimer’s disease (ad) therapy, particularly monoclonal antibodies targeting amyloid beta oligomers. Notable studies such as Avgerinos et al. (2021) and Bateman et al. (2022), showcased significant cognitive decline reductions in ad patients. Positive outcomes were also observed with gantenerumab, lecanemab, and donanemab. Additionally, alternative approaches such as Zanthoxylum caribaeum extract and herbal extracts were explored. The synthesis underscored the complexity of ad treatment and the necessity for continued multidisciplinary research. Conclusions This systematic review provides valuable insights into ad therapeutics, guiding future research directions and informing clinical practice to better meet the needs of ad patients and their caregivers. Despite significant advancements, challenges persist in developing effective ad therapies, underscoring the ongoing need for research, particularly in immunotherapy and natural compounds, to address the multifaceted nature of the disease and enhance patient outcomes.